Liminatus Pharma (LIMN) Gains from Investment Securities (2025 - 2026)

Liminatus Pharma (LIMN) posted Gains from Investment Securities of $4178.0 for Q1 2026, up 104.43% sequentially from -$94335.0 in Q4 2025.

Liminatus Pharma (LIMN) Gains from Investment Securities (2025 - 2026) Analysis & Trends

Liminatus Pharma has reported Gains from Investment Securities for 2 years, with the latest figure at $4178.0 in Q1 2026.

Quarterly Gains from Investment Securities changed N/A year-over-year to $4178.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$50134.0 (changed N/A YoY) and the FY2025 annual result came in at -$54312.0, changed N/A from the prior year.
Gains from Investment Securities rose to $4178.0 in Q1 2026 per LIMN's latest filing, from -$94335.0 in the prior quarter.
Over five years, Gains from Investment Securities peaked at $116894.0 in Q2 2025 and troughed at -$94335.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Liminatus Pharma	256.03 Mn	256.03 Mn	-

Download Data